Replies to post #162161 on Cytodyn Inc (CYDY)

[Scooter McCabe]

Even with approval CYDY may not end up being profitable. All these financing deals are racking up debt. So if it gets approved for just HIV, those proceeds may just end up going to cover debt. It's not like CYDY is going to hit it's max market share of the HIV market in one quarter. The debt risk looks like this:

Cost of Studies
Cost Of Studies having to be redone
Cost of Supplies
Cost of Supplies for redone studies
Financing Deals
Financing Deals II
Interest Payments
Legal Fees
Money Reserved for Settlement Or Damages
Compensation Packages
Advertising Fees for Proactive
Previous Outstanding Debt
State and Federal Taxes
Cost Of Manufacturing Pending Approval

50 million covers all of that? Doubtful.

[djjazzyjeff]

Nader never PR's bad news. Cytodyn is rife with failed trials and dead ends yet if you look not a single negative PR. I mean that alone is lawsuit worthy but it also means there will never be an obvious CYDY crash, it will be a slow bleed as his pump PR's have more and more diminishing returns.

[DonDonDonDon]

It seems pretty obvious that CYDY is headed down to the $2.40-$2.60 range. It likes that range a lot. One piece of slightly bad news will send it tumbling to $2.00.

Written on April 28th.